6533b7d3fe1ef96bd12601c3

RESEARCH PRODUCT

Polyoxygenated Cyclohexenes and Other Constituents of Cleistochlamys kirkii Leaves.

Fangfang PanSandra DuffyJoan J. E. MunissiMáté ErdélyiVicky M. AveryJohn P. HolleranPaul A. FitzpatrickStephen S. NyandoroStephen S. NyandoroKari RissanenAmra GruhonjicRakesh PuttreddyJerry Pelletier

subject

Double bondStereochemistryCyclohexenesPlasmodium falciparumCyclohexenePharmaceutical ScienceBreast Neoplasms01 natural sciencesAnalytical Chemistrychemistry.chemical_compoundAntimalarialsInhibitory Concentration 50X-Ray DiffractionDrug DiscoveryCyclohexenesHumansta116metabolitesCleistochlamys kirkiiButenolidePharmacologychemistry.chemical_classificationMolecular Structure010405 organic chemistryOrganic Chemistryspectrometric analysesMass spectrometricAntineoplastic Agents Phytogenic3. Good health0104 chemical sciencesPlant Leaves010404 medicinal & biomolecular chemistryCleistophenolideHEK293 CellsComplementary and alternative medicinechemistryMolecular Medicine

description

Thirteen new metabolites, including the polyoxygenated cyclohexene derivatives cleistodiendiol (1), cleistodienol B (3), cleistenechlorohydrins A (4) and B (5), cleistenediols A-F (6-11), cleistenonal (12), and the butenolide cleistanolate (13), 2,5-dihydroxybenzyl benzoate (cleistophenolide, 14), and eight known compounds (2, 15-21) were isolated from a MeOH extract of the leaves of Cleistochlamys kirkii. The purified metabolites were identified by NMR spectroscopic and mass spectrometric analyses, whereas the absolute configurations of compounds 1, 17, and 19 were established by single-crystal X-ray diffraction. The configuration of the exocyclic double bond of compound 2 was revised based on comparison of its NMR spectroscopic features and optical rotation to those of 1, for which the configuration was determined by X-ray diffraction. Observation of the co-occurrence of cyclohexenoids and heptenolides in C. kirkii is of biogenetic and chemotaxonomic significance. Some of the isolated compounds showed activity against Plasmodium falciparum (3D7, Dd2), with IC

10.1021/acs.jnatprod.6b00759https://pubmed.ncbi.nlm.nih.gov/28001067